Profil
Dr. J.
M.
Simard is on the Board of Directors at Remedy Pharmaceuticals, Inc.
Dr. Simard was previously employed as an Advisory Board Member by Carrot Capital LLC.
He received his undergraduate degree from St. Anselm College and a doctorate degree from Creighton University.
Aktive Positionen von J. Marc Simard
| Unternehmen | Position | Beginn |
|---|---|---|
Remedy Pharmaceuticals, Inc.
Remedy Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical stage pharmaceutical company that develops molecule drugs for acute central nervous system disorders | Direktor/Vorstandsmitglied | - |
Ehemalige bekannte Positionen von J. Marc Simard
| Unternehmen | Position | Ende |
|---|---|---|
Embark Healthcare
Embark Healthcare Investment ManagersFinance Embark Healthcare invests in companies located in the United States. The firm focuses on companies operating in the fields of healthcare industry. It provides financing for seed and early-stage capital requirements. | Corporate Officer/Principal | - |
Ausbildung von J. Marc Simard
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 4 |
|---|---|
Creighton University
Creighton University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
St. Anselm College
St. Anselm College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Embark Healthcare
Embark Healthcare Investment ManagersFinance Embark Healthcare invests in companies located in the United States. The firm focuses on companies operating in the fields of healthcare industry. It provides financing for seed and early-stage capital requirements. | Finance |
Remedy Pharmaceuticals, Inc.
Remedy Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical stage pharmaceutical company that develops molecule drugs for acute central nervous system disorders | Health Technology |
















